C12N 2710/16134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16134 (Use of virus or viral component as vaccine) appears on 258 US grants and 467 published applications in this corpus.
Search patents in C12N- Granted patents
- 258
- Published applications
- 467
- Assignees
- 197
- Inventors
- 739
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 1 | 2 |
| 2003 | 3 | 5 |
| 2004 | 4 | 9 |
| 2005 | 1 | 4 |
| 2006 | 2 | 4 |
| 2007 | 2 | 2 |
| 2008 | 3 | 9 |
| 2009 | 2 | 7 |
| 2010 | 3 | 8 |
| 2011 | 3 | 7 |
| 2012 | 3 | 5 |
| 2013 | 6 | 16 |
| 2014 | 3 | 22 |
| 2015 | 4 | 18 |
| 2016 | 14 | 17 |
| 2017 | 9 | 20 |
| 2018 | 16 | 23 |
| 2019 | 16 | 26 |
| 2020 | 17 | 36 |
| 2021 | 19 | 41 |
| 2022 | 22 | 53 |
| 2023 | 26 | 49 |
| 2024 | 24 | 33 |
| 2025 | 19 | 32 |
| 2026 | 10 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- High affinity engineered T-cell receptors targeting cmv infected cells9 Jun 2026US 12,649,772 B2Board of Regents, The University of Texas System
- Methods and vaccines for inducing immune responses to multiple different MHC molecules12 May 2026US 12,622,956 B2Mayo Foundation for Medical Education and Research
- Chimeric antigen receptors against human cytomegalovirus12 May 2026US 12,624,083 B2City of Hope
- Modified cytomegalovirus proteins and stabilized complexes27 Aug 2026US 2026/0250330 A1Glaxosmithkline Biologicals SA
- Human cytomegalovirus gb polypeptide20 Aug 2026US 2026/0240988 A1Pfizer Inc.
- T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus6 Aug 2026US 2026/0224692 A1The General Hospital Corporation
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors16 Jul 2026US 2026/0199414 A1Turnstone Biologics Corp.
Most cited
By later US patents
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- Human cytomegalovirus vaccine80US 10,695,419 B2ModernaTX, Inc. · 2020
- Small liposomes for delivery of immunogen encoding RNA79US 9,254,265 B2Novartis AG · 2016
- Immuno-reactive peptide CTL epitopes of human cytomegalovirus50US 6,251,399 B12001
- Human cytomegalovirus vaccine44US 11,406,703 B2ModernaTX, Inc. · 2022